1. ¹Department of Neurological Sciences, Parkinson's Disease Center, Maggiore Policlinico Hospital, IRCCS, University of Milan, Milan, Italy
2. ²Magnetic Resonance Center, Maggiore Policlinico Hospital, IRCCS, University of Milan, Milan, Italy

Correspondence: Dr Mario Rango, Department of Neurological Sciences, Parkinson's Disease Center, Maggiore Policlinico Hospital, IRCCS, University of Milan, Via F Sforza 35, Milan, Italy. E-mail: mariocristia@yahoo.it

Received 9 March 2005; Revised 11 May 2005; Accepted 13 June 2005; Published online 10 August 2005.

Abstract

In spite of several evidences for a mitochondrial impairment in Parkinson's disease (PD), so far it has not been possible to show in vivo mitochondrial dysfunction in the human brain of PD patients. The authors used the high temporal and spatial resolution 31 phosphorus magnetic resonance spectroscopy (³¹P MRS) technique, which they have previously developed in normal subjects and in patients with mitochondrial diseases to study mitochondrial function by observing high-energy phosphates (HEPs) and intracellular pH (pH) in the visual cortex of 20 patients with PD and 20 normal subjects at rest, during, and after visual activation. In normal subjects, HEPs remained unchanged during activation, but rose significantly (by 16%) during recovery, and pH increased during visual activation with a slow return to rest values. In PD patients, HEPs were within the normal range at rest and did not change during activation, but fell significantly (by 36%) in the recovery period; pH did not reveal a homogeneous pattern with a wide spread of values. Energy unbalance under increased oxidative metabolism requirements, that is, the postactivation phase, discloses a mitochondrial dysfunction that is present in the brain of patients with PD even in the absence of overt clinical manifestations, as in the visual cortex. This is in agreement with our previous findings in patients with mitochondrial disease without clinical central nervous system (CNS) involvement. The heterogeneity of the physicochemical environment (i.e., pH) suggests various degrees of subclinical brain involvement in PD. The combined use of MRS and brain activation is fundamental for the study of brain energetics in patients with PD and may prove an important tool for diagnostic purposes and, possibly, to monitor therapeutic interventions.